Co-Diagnostics, Inc. Announces Sale of Molecular Diagnostic Tests, Including Zika Virus, to Major Caribbean Laboratory
The purchasing laboratory is one of the most recognized in the country, with testing services provided to over 100,000 clients per year, ranging from general laboratory testing and routine screening to infectious disease (including the Zika virus), toxicology, pharmacology, and genetic testing. The tests included with this initial purchase are designated as Research Use Only and are expected to be used to confirm reproducibility and performance properties of the Company’s technology, with larger orders, including several tests currently in the Company’s production pipeline, anticipated to follow in Q1 2018. All tests will be run on the Mic-4 qPCR cycler manufactured by Bio Molecular Systems, with whom the Company has an OEM agreement related to branding and distribution of the instrument. The Mic software is also optimized specifically to enhance ease-of-use of the Company’s diagnostic assays.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Andrew Benson, 801-438-1036
Co-Diagnostics Investor Relations
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame